Chemotherapy and Tyrosine Kinase Inhibitors in the last month of life in patients with metastatic lung cancer: A patient file study in the Netherlands

التفاصيل البيبلوغرافية
العنوان: Chemotherapy and Tyrosine Kinase Inhibitors in the last month of life in patients with metastatic lung cancer: A patient file study in the Netherlands
المؤلفون: Adinda Mieras, Edith V. Kok, Brigitte A.H.A. Bogaarts, Lemke Pronk, Wouter Jacobs, Bregje D. Onwuteaka-Philipsen, Robin Cornelissen, Anne-Marie C. Dingemans, Alle Welling, Annemarie Becker-Commissaris, H. Roeline W. Pasman, Jan Willem van den Berg
المساهمون: Pulmonary Medicine, APH - Aging & Later Life, Pulmonary medicine, CCA - Cancer Treatment and quality of life, APH - Quality of Care, Public and occupational health, RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy, Pulmonologie, MUMC+: MA Med Staf Spec Longziekten (9)
المصدر: European Journal of Cancer Care, 29. Wiley-Blackwell Publishing Ltd
European Journal of Cancer Care. Wiley-Blackwell
Mieras, A, Becker-Commissaris, A, Pasman, H R W, Dingemans, A M M C, Kok, E V, Cornelissen, R, Jacobs, W, van den Berg, J W, Welling, A, Bogaarts, B A H A, Pronk, L & Onwuteaka-Philipsen, B D 2019, ' Chemotherapy and Tyrosine Kinase Inhibitors in the last month of life in patients with metastatic lung cancer : A patient file study in the Netherlands ', European Journal of Cancer Care . https://doi.org/10.1111/ecc.13210
European Journal of Cancer Care, 29(2):13210. Wiley
سنة النشر: 2020
مصطلحات موضوعية: Male, end of life, OSIMERTINIB, Aggressive care, Lung Neoplasms, medicine.medical_treatment, Comorbidity, chemotherapy, Targeted therapy, 0302 clinical medicine, Carcinoma, Non-Small-Cell Lung, aggressive care, Netherlands, Aged, 80 and over, Oncologists, DOCETAXEL, Terminal Care, Rehabilitation, Palliative Care, metastatic lung cancer, Age Factors, Middle Aged, END-OF-LIFE, Cancer treatment, 030220 oncology & carcinogenesis, Female, Life Sciences & Biomedicine, medicine.medical_specialty, Antineoplastic Agents, ERLOTINIB, Nursing, Tyrosine Kinase Inhibitors, cancer treatment, GEFITINIB, 03 medical and health sciences, SDG 3 - Good Health and Well-being, Internal medicine, medicine, Humans, QUALITY, In patient, Protein Kinase Inhibitors, Rapid response, Aged, Retrospective Studies, Chemotherapy, Science & Technology, business.industry, NIVOLUMAB, CARE, ONCOLOGY, Small Cell Lung Carcinoma, respiratory tract diseases, Health Care Sciences & Services, Metastatic lung cancer, PALLIATIVE CHEMOTHERAPY, business
الوصف: OBJECTIVE: Chemotherapy in the last month of life for patients with metastatic lung cancer is often considered as aggressive end-of-life care. Targeted therapy with Tyrosine Kinase Inhibitors (TKIs) is a relatively new treatment of which not much is known yet about use in the last month of life. We examined what percentage of patients received chemotherapy or TKIs in the last month of life in the Netherlands. METHODS: Patient files were drawn from 10 hospitals across the Netherlands. Patients had to meet the following eligibility criteria: metastatic lung cancer; died between June 1, 2013 and July 31, 2015. RESULTS: From the included 1,322 patients, 39% received no treatment for metastatic lung cancer, 52% received chemotherapy and 9% received TKIs. A total of 232 patients (18%) received treatment in the last month of life (11% chemotherapy, 7% TKIs). From the patients who received chemotherapy, 145 (21%) received this in the last month of life and 79 (11%) started this treatment in the last month of life. TKIs were given and started more often in the last month of life: from the patients who received TKIs, 87 (72%) received this treatment in the last month of life and 15 (12%) started this treatment in the last month of life. CONCLUSION: A substantial percentage of patient received and even started chemotherapy or TKIs in the last month of life. For chemotherapy, this might be seen as aggressive care. TKIs are said to have less side effects, do not lead to many hospital visits and due to the rapid response, are considered good palliation. However, it is not known, yet possible that, when patients still receiving treatment until shortly before death, this might influence preparing for death in a negative way. ispartof: EUROPEAN JOURNAL OF CANCER CARE vol:29 issue:2 ispartof: location:England status: published
وصف الملف: application/pdf; Print-Electronic
تدمد: 0961-5423
URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7b015c308588c35668ac639a37d5de77
https://doi.org/10.1111/ecc.13210
حقوق: OPEN
رقم الأكسشن: edsair.doi.dedup.....7b015c308588c35668ac639a37d5de77
قاعدة البيانات: OpenAIRE